1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. HUTCHMED (China) Limited
  6. News
  7. Summary
    HCM   KYG4672N1198

HUTCHMED (CHINA) LIMITED

(HCM)
  Report
Delayed London Stock Exchange  -  05/17 11:35:29 am EDT
176.00 GBX   +0.57%
11:09aAsian ADRs Move Up in Tuesday Trading
MT
05/16Appointment of Non–Executive Director
AQ
05/16HUTCHMED Limited Announces Board Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Hutchmed Commences Phase I Trial of Tumor Drug Candidate HMPL-653 in China

01/20/2022 | 04:07am EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
HUTCHMED (CHINA) LIMITED 0.57% 176 Delayed Quote.-66.98%
ON SEMICONDUCTOR CORPORATION 5.49% 58.21 Delayed Quote.-18.80%
All news about HUTCHMED (CHINA) LIMITED
11:09aAsian ADRs Move Up in Tuesday Trading
MT
05/16Appointment of Non–Executive Director
AQ
05/16HUTCHMED Limited Announces Board Changes
CI
05/05Deutsche Bank Downgrades HUTCHMED to Hold From Buy, Adjusts Price Target to $20 From $3..
MT
05/02SECTOR UPDATE : Health Care Stocks Largely Sit Out Afternoon Recovery
MT
05/02Top Midday Decliners
MT
05/02SECTOR UPDATE : Health Care Stocks Sinking with Broader Monday Markets
MT
05/02SECTOR UPDATE : Health Care
MT
05/02SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Monday
MT
05/02SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on HUTCHMED (CHINA) LIMITED
More recommendations
Financials (USD)
Sales 2022 421 M - -
Net income 2022 -376 M - -
Net cash 2022 480 M - -
P/E ratio 2022 -3,90x
Yield 2022 -
Capitalization 1 846 M 1 846 M -
EV / Sales 2022 3,24x
EV / Sales 2023 2,74x
Nbr of Employees 1 760
Free-Float 50,7%
Chart HUTCHMED (CHINA) LIMITED
Duration : Period :
HUTCHMED (China) Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUTCHMED (CHINA) LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,14 $
Average target price 4,67 $
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Wei Guo Su CEO, Executive Director & Chief Scientific Officer
Chig Fung Cheng Chief Financial Officer
Chi Keung To Executive Director
Marek Kania Chief Medical Officer & Managing Director
Karen Atkin Chief Operating Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
HUTCHMED (CHINA) LIMITED-66.98%1 835
JOHNSON & JOHNSON4.10%468 600
PFIZER, INC.-14.19%284 304
ABBVIE INC.14.82%274 733
ELI LILLY AND COMPANY8.38%269 490
ROCHE HOLDING AG-14.96%260 807